Bluebush nice article:Quote:“Typically, for Merck, the sweet...

Bluebush nice article:



Quote:
“Typically, for Merck, the sweet spot has been (to acquire them) earlier rather than later.’‘
“Unquestionably,’‘ Frazier said, “you should expect more deal activity and more product-driven business development.’‘
In 2010, Merck purchased Inspire Pharmaceuticals, a specialty drug company.
Frazier also said the nature of areas such as Hepatitis C, where new medicines are developed as cocktail or combination treatments, makes it ripe for potential partnerships. Last year, Merck won approval to sell a new Hepatitis C drug called Victrelis. The drugmaker, which is based in Whitehouse Station, later partnered with Roche on the marketing of the drug.


The heavy hitters in this industry know its about cocktail therapy at the moment and he wants aquisitions early in the pipeline.Is it too early for Biotron,maybe not considering the competition in this space.